CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids-Reference-Cited by-同舟云学术

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Published:2019-04-15 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Gonzalez-Exposito Reyes,Semiannikova Maria,Griffiths Beatrice,Khan Khurum,Barber Louise J.,Woolston Andrew,Spain Georgia,von Loga Katharina,Challoner Ben,Patel Radhika,Ranes Michael,Swain Amanda,Thomas Janet,Bryant Annette,Saffery Claire,Fotiadis Nicos,Guettler Sebastian,Mansfield David,Melcher Alan,Powles Thomas,Rao Sheela,Watkins David,Chau Ian,Matthews Nik,Wallberg Fredrik,Starling Naureen,Cunningham David,Gerlinger Marco^ORCID

Funder

Sociedad Española de Oncología Médica

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0575-3.pdf

Reference33 articles.

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal Cancer statistics , 2017. CA Cancer J Clin. 2017;67(3):177–93.

2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):iii1–9.

3. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal Cancer. N Engl J Med. 2015;372(20):1909–19.